MA56029A - Molécules de liaison au tigit et pd-1/tigit - Google Patents
Molécules de liaison au tigit et pd-1/tigitInfo
- Publication number
- MA56029A MA56029A MA056029A MA56029A MA56029A MA 56029 A MA56029 A MA 56029A MA 056029 A MA056029 A MA 056029A MA 56029 A MA56029 A MA 56029A MA 56029 A MA56029 A MA 56029A
- Authority
- MA
- Morocco
- Prior art keywords
- tigit
- binding molecules
- tigit binding
- molecules
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853816P | 2019-05-29 | 2019-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56029A true MA56029A (fr) | 2022-04-06 |
Family
ID=71070067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056029A MA56029A (fr) | 2019-05-29 | 2020-05-22 | Molécules de liaison au tigit et pd-1/tigit |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220227860A1 (fr) |
| EP (1) | EP3976652A1 (fr) |
| JP (2) | JP7241207B2 (fr) |
| KR (1) | KR20220004120A (fr) |
| CN (1) | CN113939536B (fr) |
| AR (1) | AR118980A1 (fr) |
| AU (1) | AU2020283817A1 (fr) |
| BR (1) | BR112021021795A2 (fr) |
| CA (1) | CA3139025A1 (fr) |
| CL (1) | CL2021003039A1 (fr) |
| CO (1) | CO2021015610A2 (fr) |
| CR (1) | CR20210573A (fr) |
| DO (1) | DOP2021000241A (fr) |
| EA (1) | EA202192796A1 (fr) |
| EC (1) | ECSP21085693A (fr) |
| IL (1) | IL287765A (fr) |
| JO (1) | JOP20210314A1 (fr) |
| MA (1) | MA56029A (fr) |
| MX (1) | MX2021014472A (fr) |
| PE (1) | PE20220505A1 (fr) |
| SG (1) | SG11202112725XA (fr) |
| TW (1) | TWI760751B (fr) |
| WO (1) | WO2020242919A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3047707A1 (fr) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | Proteine de fusion pd1-41bbl et ses methodes d'utilisation |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| AU2018205890B2 (en) | 2017-01-05 | 2021-09-02 | Kahr Medical Ltd. | A sirpalpha-41BBL fusion protein and methods of use thereof |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| US20240076346A1 (en) * | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| WO2023034336A2 (fr) * | 2021-08-30 | 2023-03-09 | G1 Therapeutics, Inc. | Traitements améliorés contre des cancers avancés/métastatiques avec une résistance aux inhibiteurs de points de contrôle ou une susceptibilité à une telle résistance |
| WO2023088436A1 (fr) * | 2021-11-18 | 2023-05-25 | 信达生物制药(苏州)有限公司 | Combinaison pharmaceutique comprenant un anticorps anti-pd-1 et un anticorps anti-vegf-a et son procédé d'utilisation |
| TW202409083A (zh) | 2022-05-02 | 2024-03-01 | 美商阿克思生物科學有限公司 | 抗-tigit抗體及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY183503A (en) * | 2013-07-16 | 2021-02-23 | Genentech Inc | Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| MX2016017288A (es) | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
| MY198017A (en) | 2014-08-19 | 2023-07-26 | Merck Sharp & Dohme | Anti-tigit antibodies |
| BR112017013385A2 (pt) | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | anticorpos para tigit |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN113956358A (zh) | 2015-09-25 | 2022-01-21 | 豪夫迈·罗氏有限公司 | 抗tigit抗体和使用方法 |
| AU2017313405B2 (en) | 2016-08-17 | 2024-09-26 | Compugen Ltd. | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
| JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| US10537637B2 (en) * | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| RS64576B1 (sr) * | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| AR112603A1 (es) * | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
| EP3484925B1 (fr) | 2017-07-27 | 2020-05-27 | iTeos Therapeutics SA | Anticorps anti-tigit |
| SG11202004158QA (en) * | 2017-12-28 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against tigit |
| CN113056285A (zh) * | 2018-06-29 | 2021-06-29 | 璟尚生物制药公司 | 抗肿瘤免疫检查点调节剂拮抗剂 |
-
2020
- 2020-05-19 TW TW109116479A patent/TWI760751B/zh active
- 2020-05-21 AR ARP200101441A patent/AR118980A1/es unknown
- 2020-05-22 US US17/613,675 patent/US20220227860A1/en active Pending
- 2020-05-22 CR CR20210573A patent/CR20210573A/es unknown
- 2020-05-22 MX MX2021014472A patent/MX2021014472A/es unknown
- 2020-05-22 AU AU2020283817A patent/AU2020283817A1/en active Pending
- 2020-05-22 KR KR1020217038318A patent/KR20220004120A/ko not_active Application Discontinuation
- 2020-05-22 CA CA3139025A patent/CA3139025A1/fr active Pending
- 2020-05-22 CN CN202080039788.0A patent/CN113939536B/zh active Active
- 2020-05-22 PE PE2021001860A patent/PE20220505A1/es unknown
- 2020-05-22 MA MA056029A patent/MA56029A/fr unknown
- 2020-05-22 EP EP20731763.7A patent/EP3976652A1/fr active Pending
- 2020-05-22 JO JOP/2021/0314A patent/JOP20210314A1/ar unknown
- 2020-05-22 SG SG11202112725XA patent/SG11202112725XA/en unknown
- 2020-05-22 WO PCT/US2020/034158 patent/WO2020242919A1/fr active Application Filing
- 2020-05-22 EA EA202192796A patent/EA202192796A1/ru unknown
- 2020-05-22 BR BR112021021795A patent/BR112021021795A2/pt unknown
- 2020-05-22 JP JP2021569860A patent/JP7241207B2/ja active Active
-
2021
- 2021-11-01 IL IL287765A patent/IL287765A/en unknown
- 2021-11-17 CL CL2021003039A patent/CL2021003039A1/es unknown
- 2021-11-22 CO CONC2021/0015610A patent/CO2021015610A2/es unknown
- 2021-11-25 DO DO2021000241A patent/DOP2021000241A/es unknown
- 2021-11-26 EC ECSENADI202185693A patent/ECSP21085693A/es unknown
-
2023
- 2023-03-06 JP JP2023033480A patent/JP2023071889A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3976652A1 (fr) | 2022-04-06 |
| MX2021014472A (es) | 2022-01-06 |
| PE20220505A1 (es) | 2022-04-07 |
| JP7241207B2 (ja) | 2023-03-16 |
| BR112021021795A2 (pt) | 2022-01-04 |
| TW202110884A (zh) | 2021-03-16 |
| JP2023071889A (ja) | 2023-05-23 |
| CN113939536B (zh) | 2024-05-14 |
| DOP2021000241A (es) | 2021-12-30 |
| JOP20210314A1 (ar) | 2023-01-30 |
| CA3139025A1 (fr) | 2020-12-03 |
| SG11202112725XA (en) | 2021-12-30 |
| CL2021003039A1 (es) | 2022-08-05 |
| AU2020283817A1 (en) | 2021-11-25 |
| EA202192796A1 (ru) | 2022-03-03 |
| TWI760751B (zh) | 2022-04-11 |
| CO2021015610A2 (es) | 2021-11-30 |
| JP2022533457A (ja) | 2022-07-22 |
| CR20210573A (es) | 2021-12-15 |
| WO2020242919A1 (fr) | 2020-12-03 |
| CN113939536A (zh) | 2022-01-14 |
| AR118980A1 (es) | 2021-11-17 |
| US20220227860A1 (en) | 2022-07-21 |
| IL287765A (en) | 2022-01-01 |
| ECSP21085693A (es) | 2021-12-30 |
| KR20220004120A (ko) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56029A (fr) | Molécules de liaison au tigit et pd-1/tigit | |
| MA52785A (fr) | Molécules de liaison dirigées contre bcma et leurs utilisations | |
| DK3472207T3 (da) | Bindingsmolekyler, der binder pd-l1 og lag-3 | |
| DK3476399T3 (da) | Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf | |
| MA44670A (fr) | Protéines de liaison trispécifiques et/ou trivalentes | |
| MA43816A (fr) | Protéines de liaison inductibles et méthodes d'utilisation | |
| MA50059A (fr) | Molécules de liaison spécifiques d'asct2 et leurs utilisations | |
| DK3370768T3 (da) | Antistoffer som specifikt binder pd-1 og anvendelser deraf | |
| MA50942A (fr) | Protéines de liaison à l'adn modifiées | |
| DK3981792T3 (da) | PD-1-bindende molekyler og fremgangsmåder til anvendelse deraf | |
| MA55472A (fr) | Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules | |
| DK3710484T3 (da) | Ctla-4-bindende antistoffer og anvendelser deraf | |
| GB2595980B (en) | Anti-TCR antibody molecules and uses thereof | |
| IL280004A (en) | Antibody molecules that bind PD-L1 and CD137 | |
| MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
| MA47508A (fr) | Protéines de liaison à cd33, nkg2d et cd16 | |
| GB2598218B (en) | Anti-TCR antibody molecules and uses thereof | |
| EP3613771A4 (fr) | Molécule de liaison spécifique à protéine lrig-1 et son utilisation | |
| IL288314A (en) | Anti-tdp-43 binding molecules and uses thereof | |
| IL289964A (en) | Multimeric anti-cd123 bispecific binding compounds and uses thereof | |
| MA50678A (fr) | Molécules de liaison spécifiques de l'il-21 et leurs utilisations | |
| DK3374398T3 (da) | Bindingsmolekyler, som er specifikke for asct2, og anvendelser deraf | |
| EP3794039A4 (fr) | Anticorps de liaison à pd-1 et utilisation associée | |
| EP3882266A4 (fr) | Molécule de liaison spécifique à la protéine lrig-1, et utilisation associée | |
| EP3781202A4 (fr) | Anticorps de liaison au pd-1 et leurs utilisations |